key door icon

WD Rx Access
Healthcare Providers

If you are a physician treating patients with Wilson’s disease, we have programs that may interest you.

Health care provider people icon

We understand that the journey for Wilson's disease patients to obtain treatment can be complicated and require multiple steps. With that in mind, we have several resources that can help support your patients.

The WD Rx Access team is here to assist you with the prescribing process beginning with prescription benefit verifications, to enrolling eligible patients into our copay program.

How We Can Help You Help Patients

Co-pay and Patient Assistance Programs

WD Rx Access provides financial support to eligible* commercially insured patients by reducing their monthly co-payment to as low as $5.

dollar icon

Refer your patients without commercial insurance to the Bausch Health Patient Assistance Program to see if they are eligible to receive their medication free of charge.

Prior Authorization Processing Support

We can assist with completing the basic demographics section for prior authorization forms, follow up after submissions and report determinations back to you and your patients to streamline the processes.

Benefit Investigation/Verification

We can complete a benefit investigation and report coverage back to you and your patient, liaising among your office, your patients and their insurance providers.

dollar icon
Pharmacy Shipment Coordination

Following confirmation of benefits and prior authorization, we send the prescription directly to the pharmacy and assist in shipment coordination and follow up with the pharmacy until your patient receives their medication.

Patient Outreach

We help patients understand insurance coverage and benefits, prior authorization processing support, and co-pay information. If they qualify, we’ll help them enroll in our co-pay assistance program and, once enrolled, we’ll send annual re-verification emails reminding them when it’s time to re-enroll.

dollar icon
Nursing Program

WD Rx Access offers the support of a dedicated licensed nurse who provides one-on-one treatment assistance for patients. Our nursing coaches also share helpful tips on diet, communicating about Wilson’s disease and overall disease management.


Patient Education Materials includes educational information for Wilson’s disease patients and caregivers, such as recommendations for copper-conscious cooking, testimonials from the Wilson’s disease community, guides to having tough conversations and more. All of these resources are available free to all patients regardless of therapy.

View full PDF of program offerings here


For any additional questions, please call
888-607-7267 or fill out the following form

For more information on WD Rx Access and
your medication, please select the product
you’ve been prescribed:

Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.


CUPRIMINE® (penicillamine) is indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis.

  • Except for the treatment of Wilson's disease or certain patients with cystinuria, use of penicillamine during pregnancy is contraindicated. Mothers on therapy with penicillamine should not nurse their infants.
  • Patients with a history of penicillamine-related aplastic anemia or agranulocytosis should not be restarted on penicillamine. Because of its potential for causing renal damage, penicillamine should not be administered to rheumatoid arthritis patients with a history or other evidence of renal insufficiency.
  • The use of penicillamine has been associated with fatalities due to certain diseases such as aplastic anemia, agranulocytosis, thrombocytopenia, Goodpasture's syndrome, and myasthenia gravis.
  • Routine urinalysis, white and differential blood cell count, hemoglobin determination, direct platelet count, together with monitoring of the patient's skin, lymph nodes and body temperature, must be done twice weekly for the first month, every two weeks for the next five months and monthly thereafter. Patients should be instructed to report promptly the development of signs and symptoms of granulocytopenia and/or thrombocytopenia such as fever, sore throat, chills, bruising or bleeding.
  • A reduction in WBC count below 3500/mm3 requires discontinuation. Platelet count below 100,000/mm3 even in absence of clinical bleeding or a progressive fall in either platelet or WBC count in three successive determinations requires at least temporary cessation of therapy even though values are still within the normal range.
  • Proteinuria and/or hematuria may develop during therapy and may be warning signs of membranous glomerulopathy which can progress to a nephrotic syndrome. Proteinuria which exceeds 1 g/24 hours, or proteinuria which is progressively increasing, requires either discontinuance of the drug or a reduction in the dosage. When penicillamine is used in cystinuria, an annual x-ray for renal stones is advised.
  • Because of rare reports of intrahepatic cholestasis and toxic hepatitis, liver function tests are recommended every six months for the duration of therapy. In Wilson's disease, these are recommended every three months, at least during the first year of treatment.
  • Onset of new or worsening of existing neurological symptoms has been reported during initiation of therapy with CUPRIMINE. Myasthenic syndrome sometimes progressing to myasthenia gravis has been reported. In the majority of cases, symptoms of myasthenia have receded after withdrawal of penicillamine.
  • When pemphigus is suspected, CUPRIMINE should be discontinued.
  • Penicillamine can cause fetal harm when administered to a pregnant woman. Penicillamine should not be administered to pregnant women with cystinuria or rheumatoid arthritis and should be discontinued promptly in patients in whom pregnancy is suspected or diagnosed.
  • Penicillamine should be used in women of childbearing potential only when the expected benefits outweigh the possible hazards. However, for patients with Wilson’s disease reported experience shows that continued treatment with penicillamine throughout pregnancy protects the mother against relapse of the Wilson's disease, and discontinuation of penicillamine has deleterious effects on the mother, which may be fatal. If penicillamine is administered during pregnancy to patients with Wilson’s disease, it is recommended that the daily dose be limited to 750 mg. If cesarean section is planned, the daily dose should be reduced to 250 mg, but not lower, for the last six weeks of pregnancy and postoperatively until wound healing is complete.
  • Some patients may experience drug fever with or without macular cutaneous eruptions. Penicillamine should be temporarily discontinued in these patients if being treated for Wilson's disease or cystinuria until the reaction subsides. In the case of drug fever in rheumatoid arthritis patients, because other treatments are available, penicillamine should be discontinued.
  • The skin and mucous membranes should be observed for allergic reactions. Rashes have occurred. Less commonly, a late rash may be seen, usually after six months or more of treatment, and requires discontinuation of penicillamine.
  • The appearance of a drug eruption accompanied by fever, arthralgia, lymphadenopathy or other allergic manifestations usually requires discontinuation of penicillamine.
  • Penicillamine should not be used in patients who are receiving concurrently gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone because these drugs are also associated with similar serious hematologic and renal adverse reactions. Patients who have had gold salt therapy discontinued due to a major toxic reaction may be at greater risk of serious adverse reactions with penicillamine but not necessarily of the same type.
  • Patients who are allergic to penicillin may theoretically have cross-sensitivity to penicillamine.
  • Patients with Wilson's disease, rheumatoid arthritis, or cystinuria should be given 25 mg/day of pyridoxine during therapy, since penicillamine increases the requirement for this vitamin. Patients also may receive benefit from a multivitamin preparation. In Wilson's disease, multivitamin preparations must be copper-free. Mineral supplements should not be given, since they may block the response to penicillamine.
  • The effects of penicillamine on collagen and elastin make it advisable to consider a reduction in dosage to 250 mg/day when surgery is contemplated. Restitution of full therapy should be delayed until wound healing is complete.
  • Penicillamine is a drug with a high incidence of untoward reactions, some of which are potentially fatal.
  • Reported incidences for the most commonly occurring adverse reactions in rheumatoid arthritis patients based on 17 representative clinical trials reported in the literature (1270 patients) include events related to Allergy: pruritis, rashes, pemphigus; Gastrointestinal: anorexia, epigastric pain, nausea, vomiting, or occasional diarrhea, hepatic dysfunction, effect on taste perception and oral ulcerations; Hematological: leukopenia, thrombocytopenia leading to fatalities; Renal: proteinuria and/or hematuria progressing to nephrotic syndrome, renal failure; Central Nervous System: tinnitus, optic neuritis, peripheral sensory and motor neuropathies, muscular weakness, visual and psychic disturbances, mental disorders, agitation and anxiety; Neuromuscular: myasthenia gravis, dystonia. Other: Adverse reactions reported rarely include thrombophlebitis, hyperpyrexia, alopecia, lichen planus, polymyositis, dermatomyositis, mammary hyperplasia, elastosis perforans serpiginosa, toxic epidermal necrolysis, anetoderma, and Goodpasture's syndrome. Vasculitis, including fatal renal vasculitis, allergic alveolitis, obliterative bronchiolitis, interstitial pneumonitis, pulmonary fibrosis, and bronchial asthma also have been reported.

Please click here for full Prescribing Information for CUPRIMINE including Boxed Warning

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-FDA-1088.


SYPRINE® ) is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine. Clinical experience with SYPRINE is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. SYPRINE and penicillamine cannot be considered interchangeable. SYPRINE should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.

Unlike penicillamine, SYPRINE is not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, SYPRINE was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.

SYPRINE is not indicated for treatment of biliary cirrhosis.

  • SYPRINE is contraindicated in patients hypersensitive to SYPRINE. Patients should be observed closely for signs of possible hypersensitivity.
  • Patients receiving SYPRINE should remain under regular medical supervision throughout the period of drug administration. Patients (especially women) should be closely monitored for evidence of iron deficiency anemia.
  • The treatment can be monitored by the determination of free copper in the serum. Therapy may be monitored with a 24-hour urinary copper analysis periodically (i.e., every 6-12 months).
  • Patients should be directed to take SYPRINE on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. The capsules should be swallowed whole with water and should not be opened or chewed.
  • For the first month of treatment, the patient should have his temperature taken nightly, and he should be asked to report any symptom such as fever or skin eruption.
  • In general, mineral supplements should not be given since they may block the absorption of SYPRINE. However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilson’s disease.
  • SYPRINE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SYPRINE is administered to a nursing mother.
  • The following adverse reactions have been reported in a clinical study: iron deficiency and systemic lupus erythematosus. In addition, dystonia, muscular spasm, myasthenia gravis have been reported in marketed use.

Please click here for full Prescribing Information for SYPRINE.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-FDA-1088.